The Future of Jack Inhibitors

Dr. Schwartzman: With any new treatment development we really want to raise that bar from ACR 20 to ACR 50 it's not correct. Jack inhibitors are very effective therapies and if we look at the safety data even though there have been new identified adverse events they don't all have comparator trials with other therapies, he says. We hope you enjoyed this episode of Sound Bites for people with psoriasis and psoriatic arthritis. For more information about the ins and outs of treatment options contact our patient navigation center by calling 800-723-9166 option 1 today.